IQWiG assessment suggests Nulojix (belatacept) offers considerable added benefit after kidney transplant-BMS
After a first early benefit assessment in April 2012 assessing Nulojix (belatacept), from BMS, for adults after a kidney transplant, the German Institute for Quality and Efficiency in Health Care (IQWiG) has reexamined whether the drug offers an added benefit over the appropriate comparator therapy. The first dossier showed an indication of minor added benefit only in a certain type of donor. However an indication of considerable added benefit in comparison with ciclosporin A can be derived from the second dossier.
Long-term data showed no relevant differences between the treatment groups regarding mortality. Belatacept had an advantage in renal insufficiency, however: this occurred less frequently in transplanted patients with advanced-stage chronic kidney disease (stage 4/5). IQWiG assessed this as an indication of considerable added benefit. Data also showed an advantage of belatacept in the composite outcome “death or graft loss”, which IQWiG assessed as a hint of an added benefit. Overall, IQWiG therefore sees an indication of considerable added benefit of belatacept in comparison with ciclosporin A.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.